The right decision-making, treatment and our health depend on accurate diagnosis on time, yet we face limited access, high inefficiency and high costs.
3 700 000 000
people have limited access to critical diagnostics today.
Our patent protected technology has been developed through +10 years of state-of-the-art biochemistry and nanotechnology R&D. With our isothermal amplification and unique biosensing method, we enable highly multiplexed and low-cost detection of biomarkers directly at the point of care.
First point-of-care solution for dual nucleic acid and protein detection, applicable for different disease areas.
High-accuracy multiplexing for accurate diagnosis and improved clinical outcome.
Rapid results in minutes, instead of days, for faster decision-making and treatment.